Pyrrolo-pyridine kinase modulators

Details Pyrrolo-pyridine kinase modulators Pyrrolo-pyridine kinase modulators

2008-02-29

2009-10-13

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S234500, C514S253040, C514S300000

Reexamination Certificate

active

07601839

ABSTRACT:
The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.

REFERENCES:
patent: 5019586 (1991-05-01), Oxford et al.
patent: 5051412 (1991-09-01), Macor
patent: 5338849 (1994-08-01), Festal et al.
patent: 5563150 (1996-10-01), Curtis et al.
patent: 5643734 (1997-07-01), Henderson
patent: 5681959 (1997-10-01), Bishop et al.
patent: 6335342 (2002-01-01), Longo et al.
patent: 6589950 (2003-07-01), Collingwood et al.
patent: 6699883 (2004-03-01), Doemling et al.
patent: 2002/0119982 (2002-08-01), Wang et al.
patent: 2004/0019052 (2004-01-01), Garland et al.
patent: 2007/0043068 (2007-02-01), Arnold et al.
patent: 10053122 (2001-05-01), None
patent: 1995915 (2001-08-01), None
patent: WO-1996-32391 (1996-10-01), None
patent: WO-2000-43393 (2000-07-01), None
patent: WO-2000-71537 (2000-11-01), None
patent: WO-2002-051837 (2002-07-01), None
patent: WO-2002-051837 (2002-07-01), None
patent: WO-2003-002563 (2003-01-01), None
patent: WO-2003-24969 (2003-03-01), None
patent: WO-2003-28724 (2003-04-01), None
patent: WO-2003-045949 (2003-06-01), None
patent: WO-2003-068221 (2003-08-01), None
patent: WO-2003-068773 (2003-08-01), None
patent: WO-2003-82868 (2003-10-01), None
patent: WO-2003-82869 (2003-10-01), None
patent: WO-2004-014368 (2004-02-01), None
patent: WO-2004-024895 (2004-03-01), None
patent: WO-2004-032874 (2004-04-01), None
patent: WO-2004-078756 (2004-09-01), None
patent: WO-2004-078756 (2004-09-01), None
patent: WO-2004-078757 (2004-09-01), None
patent: WO-2004-078757 (2004-09-01), None
patent: WO-2004-101565 (2004-11-01), None
patent: WO-2004-101565 (2004-11-01), None
patent: WO-2005-062795 (2005-07-01), None
patent: WO-2005-062795 (2005-07-01), None
patent: WO-2005-085244 (2005-09-01), None
patent: WO-2005-095400 (2005-10-01), None
patent: WO-2006-015123 (2006-02-01), None
patent: WO-2003-087816 (2006-10-01), None
patent: WO-2006-124863 (2006-11-01), None
patent: WO-2007-106236 (2007-09-01), None
patent: WO-2007-106236 (2007-09-01), None
PCT/US05/26792 Search Report dated Nov. 28, 2005.
PCT/US07/002123 Search Report dated Dec. 21, 2007.
Adamczyk et al., “Synthesis of 3,7-dihydroimidazol[1,2a]pyrazine-3-ones and their chemiluminescent properties,” Tetrahedron 59:8129-8143 (2003).
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucl. Acids Res. 24:3389-3402 (1997).
Arduengo et al., “Low-Coordinate Carbene Complexes of Nickel(0)and Platinum(0)†,” J. Am. Chem. Soc. 116:4391-4394 (1994).
Arduengo et al., “Adducts of Carbenes with Group II and XII Metallocenes,” Organometallics 17:3375-3382 (1998).
Bach et al., “Synthesis of 2'-Substituted 4-Bromo-2,4' -bithiazoles by Regioselective Cross-Coupling Reactions,” J. Org. Chem. 67:5789-5795 (2002).
Berge et al., “Pharmaceutical Salts,” J. Pharma. Sci. 66:1-19 (1977).
Blaney, J.M. and Dixon, J.S., “A good ligand is hard to find: Automated docking methods,” Perspectivesin Drug Discovery and Design 1:301-319 (1993).
Bolm et al., “Iron-Catalyzed Reactions in Organic Synthesis,” Chem. Rev. 104:6217-6254 (2004).
Boudier et al., “New Applications of Polyfunctional Organometallic Compounds in Organic Synthesis,” Angew. Chem. Int. Ed. 39: 4414-4435 (2000).
Brooks et al., “CHARMM: A program for macromolecular energy, minimization, and dynamics calculations,” J. Comp. Chem. 4:187-217 (1983).
Charifson et al., “Consensus Scoring: A Method for Obtaining Improved Hit Rates from Docking Databases of Three-Dimensional Structures into Proteins,” J. Med. Chem. 42:5100-5109 (1999).
Crabtree, S. et al., “Facile and Gentle Method for Quantitative Lysis ofEscherichia coliandSalmonella typhimurium,” J. Bacteriol. 158(1):354-356 (1984).
Deininger, M. et al., “The development of imatinib as a therapeutic agent for chronic myeloid leukemia,” Blood 105(7):2640-2653 (2005).
Feldman et al. “Novel Small Molecule Inhibitors of 3-Phosphoinositide-Dependent Kinase-1 (PDK1),” JBC Papers in Press, Published Mar. 16, 2005 Manuscript M501367200.
Furstner et al., “Iron-Catalyzed Cross-Coupling Reactions,” J. A. Chem. Soc. 124:13856-13863 (2002).
Goodsell & Olsen, “Automated Docking of Substrates to Proteins by Simulated Annealing,” Proteins: Structure, Function and Genetics 8:195-202 (1990).
Harrington et al., “VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo,” Nature Medicine Advance Online Publication Feb. 22, 2004, pp. 1-6.
Hartwig, Acc. “Carbon-Heteroatom Bond-Forming Reductive Eliminations of Amines, Ethers, and Sulfides,” Chem. Res. 31:852-860 (1998).
Ishiyama et al., “Paladium (0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylvoboronic Esters,” J. Org. Chem. 60:7508-7510 (1995).
Ji et al., “Selective Amination of Polyhalopyridines Catalyzed by a Palladium-Xantphos Complex,” Org. Lett. 5:4611-4614 (2003).
Jones et al., “Molecular Recognition of Receptor Sites using a Genetic Algorithm with a Description of Desolvation,” J. Mol. Biol. 245:43-53 (1995).
Kuntz et al., “A Geometric Approach to Macromolecule-Ligand Interactions,” J. Mol. Biol. 161:269-288 (1982).
Ley et al., “Modern Synthetic Methods for Copper-Mediated C(aryl)-0, C(aryl)-N, and C(aryl)-S Bond Formation,” Angew Chem. 42:5400-5449 (2003).
Littke et al., “Palladium-Catalyzed Coupling Reactions of Aryl Chlorides,” Angew. Chem. 41:4176-4211 (2002).
Maryanoff et al., “The Wittig Olefination Reaction and Modifications Involving Phosphoryl-Stabilized Carbanions. Stereochemistry, Mechanism, and Selected Synthetic Aspects,” Chem. Rev. 89:863-927 (1989).
Matsui, T. et al., “Expression of Unphosphorylated Form of Human Double-Stranded RNA-Activated Protein Kinase inEscherichia coli,” Biochem. Biophys. Res. Commun. 284:798-807 (2001)
Meng et al., “Automated Docking with Grid-Based Energy Evaluation,” J. Comp. Chem. 13:505-524 (1992).
Molander et al., “Palladium-Catalyzed Suzuki-Miyaura Cross-Coupling Reactions of Potassium Aryl-and Heteroarylatrifluoroborates,” J. Org. Chem. 68:4302-4314 (2003).
Molander et al., “B-Alkyl Suzuki-Miyaura Cross-Coupling Reactions with Air-Stable Potassium Alkyltrifluoroborates,” J. Org. Chem. 68:5534-5539 (2003).
Mongin et al., “Advances in the directed metallation of azines and diazines (pyridines, pyrmimidines, pyrazines, pyrizadines, quinolines, benzodiazines and carbolines). Part 1: Metallation of pyridines, quinolines and carbolines,” Tetrahedron 57:4059-4090 (2001).
Nahm et al., “N-Methoxy-N-Methylamides as Effective Acylating Agents,” Tetrahedron Lett. 22(39):3815-3818 (1981).
Rarey et al., “A Fast Flexible Docking Method using an Incremental Construction Algorithm,” J. Mol. Biol. 261:470-489 (1996).
Sakamoto et al., “Condensed Heteroaromatic Ring Systems. XXII. Simple and General Synthesis of 1H-Pyrrolo-Pyridines,” Heterocycles 34(12): 2379-84 (1992).
Sapountzis et al., “A New General Preparation of Polyfunctional Diarylamines by the Addition of Functionalized Arylmagnesium Compounds to Nitroarenes,” J. Am. Chem. Soc. 124:9390-9391 (2002).
Thompson et al. “DbClustal: rapid and reliable global multiple alignments of protein sequences detected by database searches,” Nucl. Acids Res. 28:2919-2926 (2000).
Travis et al., “Proteins and Organic Solvents Make an Eye-Opening Mix,” Science 262:1374 (1993).
Turck et al., Advances in the directed metallation of azines and diazines (pyridines, pyrimidines, pyrazines, pyridazines, quinolines, benzodiazines and carbolines). Part 2. Metallation of pyrimi

Affiliated with

Also associated with

Rating

Pyrrolo-pyridine kinase modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolo-pyridine kinase modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo-pyridine kinase modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4083252